Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Hagberg

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medical Case Reports|June 29, 2010
Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case reportAlan M Edwards, Hans Hagberg
Rhinology|November 2, 2010
Chemotherapy in severe nasal polyposis--a possible beneficial effect? A report of three casesMonika Stenkvist Asplund, Hans Hagberg, Mats Holmström
Leukemia & Lymphoma|July 2, 2011
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry studyTove Wästerlid, Björn Jonsson, Hans Hagberg, et al.
Acta Oncologica (Stockholm, Sweden)|June 11, 2014
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma RegistryFredrik Ellin, Mats Jerkeman, Hans Hagberg, et al.
Blood Advances|June 16, 2018
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)Kristina Drott, Hans Hagberg, Karin Papworth, et al.
Lakartidningen|May 7, 2002
[Cataract in children after autologous bone marrow transplantation. A common, but curable complication]Per Frisk, Hans Hagberg, Agneta Mandahl, et al.
Medical Oncology (Northwood, London, England)|May 25, 2006
Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)Magdalena Adde, Gunilla Enblad, Hans Hagberg, et al.
Acta Haematologica|July 8, 2010
Acquired haemophilia A and Kaposi's sarcoma in an HIV-negative, HHV-8-positive patient: a discussion of mechanism and aetiologyPeter Cashin, Lars Göran Lundberg, Hans Hagberg, et al.
Lakartidningen|November 22, 2005
[Limit investigation in cancer of unknown primary site]Ake Berglund, Peter Nygren, Hans Hagberg, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2008
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in SwedenFrida Kasteng, Martin Erlanson, Hans Hagberg, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medical Case Reports|June 29, 2010
Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case reportAlan M Edwards, Hans Hagberg
Rhinology|November 2, 2010
Chemotherapy in severe nasal polyposis--a possible beneficial effect? A report of three casesMonika Stenkvist Asplund, Hans Hagberg, Mats Holmström
Leukemia & Lymphoma|July 2, 2011
Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry studyTove Wästerlid, Björn Jonsson, Hans Hagberg, et al.
Acta Oncologica (Stockholm, Sweden)|June 11, 2014
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma RegistryFredrik Ellin, Mats Jerkeman, Hans Hagberg, et al.
Blood Advances|June 16, 2018
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)Kristina Drott, Hans Hagberg, Karin Papworth, et al.
Lakartidningen|May 7, 2002
[Cataract in children after autologous bone marrow transplantation. A common, but curable complication]Per Frisk, Hans Hagberg, Agneta Mandahl, et al.
Medical Oncology (Northwood, London, England)|May 25, 2006
Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)Magdalena Adde, Gunilla Enblad, Hans Hagberg, et al.
Acta Haematologica|July 8, 2010
Acquired haemophilia A and Kaposi's sarcoma in an HIV-negative, HHV-8-positive patient: a discussion of mechanism and aetiologyPeter Cashin, Lars Göran Lundberg, Hans Hagberg, et al.
Lakartidningen|November 22, 2005
[Limit investigation in cancer of unknown primary site]Ake Berglund, Peter Nygren, Hans Hagberg, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2008
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in SwedenFrida Kasteng, Martin Erlanson, Hans Hagberg, et al.
Pageof 5